A method for magnetic cellular manipulation may include contacting a composition with a biological sample to form a mixture. The composition may include a plurality of particles. Each particle in the plurality of particles may include a magnetic substrate. The magnetic substrate may be characterized by a magnetic susceptibility greater than zero. The composition may also include a chargeable silicon-containing compound. The chargeable silicon-containing compound may coat at least a portion of the magnetic substrate. The biological sample may include cells and/or cellular structures. The method may also include applying a magnetic field to the mixture to manipulate the composition.

A heterogeneous population of cells are separated and collected according to a method. The heterogeneous population of cells in a paramagnetic medium are placed in a fluidic channel in which the fluidic channel comprises two or more outlets. The heterogeneous population of cells in the fluidic channel are separated based on differences in magnetic susceptibility and density of the heterogeneous population of cells. Fluid comprising the separated cells is withdrawn from the two or more outlets using variable flow rates by fluidic pumps at respective ones of the two or more outlets simultaneously to fractionalize the fluid comprising the separated cells across the two or more outlets by manipulation of the variable flow rates relative to one another.

Highly proliferative mesenchymal stem cells (MSCs) may be useful for the large-scale and rapid production of a cell preparation, and a cell population may include the mesenchymal stem cells. A cell population may include mesenchymal stem cells derived from a fetal appendage, wherein, in the cell population, the proportion of CD105.sup.+ mesenchymal stem cells is 50% or more, the proportion of CD200.sup.+ mesenchymal stem cells is less than 10%, and the proportion of CD106.sup.+ mesenchymal stem cells is less than 5%.

A method of measuring risk assessment in a patient with appendicitis is disclosed. The method comprises: (a) measuring the TRAIL protein level in a blood sample of the patient; and (b) providing a risk assessment based on the TRAIL protein level.

The present invention provides devices and systems for use at the point of care. The methods devices of the invention are directed toward automatic detection of analytes in a bodily fluid. The components of the device are modular to allow for flexibility and robustness of use with the disclosed methods for a variety of medical applications.

High efficiency methods for producing retinal pigment epithelial cells from induced pluripotent stem cells (iPSCs) are disclosed herein. The iPSCs are produced from somatic cells, including retinal pigment epithelial (RPE) cells, such as fetal RPE stem cells. In some embodiments, the iPSC include a tyrosinase promoter operably linked to a marker. Methods are disclosed for using the RPE cells, such as for treatment. Methods for screening for agents that affect RPE differentiation are also disclosed.

The present invention aims to obtain a method for quality evaluation of human mesenchymal stem cells, a method for isolation, selection and culture of human mesenchymal stem cells, a cell population of rapidly proliferating human mesenchymal stem cells, as well as monoclonal antibodies that specifically recognize rapidly proliferating human mesenchymal stem cells. From a cell population containing human mesenchymal stem cells, rapidly proliferating human mesenchymal stem cells are isolated, selected and cultured. The abundance ratio of cells expressing Ror2 or Fzd5 in the cell population thus isolated, selected and cultured is quantified to determine whether or not each cell population is acceptable.

The invention is directed to a Method for detecting differentiated hematopoietic cells comprising the steps: a) isolation of undifferentiated hematopoietic stem cells in groups of 1-1000 cells on a support b) proliferating the isolated cells to form cell colonies of differentiated hematopoietic cells by providing cell media comprising a growth factor c) contacting the cell colonies with one or more marker conjugates comprising at least one detection moiety and at least one antigen recognizing moiety against CD14, CD235a and CD15 d) detecting the relative amount of differentiated hematopoietic stem cells in a cell colony labelled with the marker conjugates.

The present invention relates to methods to produce an enzymatic-exchangeable peptide Major Histocompatibility Complex Class I (MHC-I) Single Chain Trimer (SCT), or tetramer thereof, constructs encoding same and uses thereof, such as detection or isolation of antigen-specific CD8.sup.+ T cells. Said SCT comprises, in order from N-terminus to C-terminus, (i) a peptide ligand, (ii) a first linker polypeptide comprising an enzyme-cleavable portion, (i11) a β-2 microglobulin (β2.Math.τ.Math.) polypeptide, (iv) a second linker polypeptide, and (v) a mature MHC-I heavy chain polypeptide. In addition, a method of defining a peptide ligand suitable for successful production of a single fusion protein for peptide exchange is claimed.

As a technology for enriching atrial myocytes or ventricular myocytes in a cardiomyocyte-containing cell population induced from stem cells, provided is a method for enriching atrial myocytes or ventricular myocytes in a cardiomyocyte-containing cell population induced from stem cells, the method including a step of collecting atrial myocytes or ventricular myocytes from the cell population by using the expression level of CD151 as an index.